Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad Laboratories Inc. (NYSE:BIO) 于2025年7月31日发布了2025年第二季度财务业绩，尽管市场环境充满挑战，公司仍实现了适度的收入增长。在财报发布当天，公司股价收于$303.71，常规交易时段上涨0.44%，但盘后交易中略微下跌0.39%。 本季度的一个重要里程碑是公司于2025年6月30日完成了对Stilla Technologies的收购，这一战略举 ...

HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Bio-Rad ...